CareDx Inc (CDNA) Actualités

Form 8-K - Current report

CareDx Announces Fourth Quarter and Full Year 2024 Financial Results

Full Year 2024 Revenue Grew 19% to $334 Million Expects Full Year 2025 Revenue of $365 Million to $375 Million CareDx, Inc. (Nasdaq: CDNA) today...

CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict

All Patent Claims Asserted Against CareDx are Found to Be Invalid CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery...

CareDxが研究結果を発表、AlloSeq cfDNAが臓器移植患者の拒絶反応検出に高い精度を示す

AlloSeq cfDNAが実績のあるAlloSure検査と同等の性能を発揮 CareDxがAlloSeq cfDNAで革新的な非侵襲的移植モニタリングを国際的に提供 （ビジネスワイヤ）...

CareDx publie une étude confirmant la grande précision d’AlloSeq cfDNA dans la détection du rejet chez les patients transplantés

L’ADN acellulaire d’AlloSeq démontre une performance équivalente aux tests AlloSure, reconnus pour leur fiabilité CareDx propose aux patients du...

CareDx gibt Studie bekannt, die zeigt, dass AlloSeq cfDNA bei der Erkennung von Abstoßungsreaktionen bei Organtransplantationspatienten äußerst genau ist

AlloSeq cfDNA entspricht der Leistung des bewährten AlloSure-Tests CareDx bringt mit AlloSeq cfDNA ein innovatives nicht-invasives...

CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients

AlloSeq cfDNA Consistent with Performance of Proven AlloSure Testing CareDx Brings Innovative Non-Invasive Transplant Monitoring to Patients...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies

New Data from the ACROBAT Study Shows AlloHeme Detects Cancer Relapse with Clinically Meaningful Lead Time CareDx, Inc. (Nasdaq: CDNA) – The...

CareDx to Report Fourth Quarter and Full Year 2024 Financial Results

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results

Fourth Quarter Revenue is Expected to Increase 30% Year-Over-Year Expects Full Year 2024 Revenue of $332 Million to $333 Million CareDx, Inc...